期刊
CELLULAR IMMUNOLOGY
卷 279, 期 1, 页码 25-29出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2012.09.001
关键词
Anti-TNF-alpha therapy; Regulatory T cell; Effector T cell
资金
- National Natural Science Foundation of China [NSFC-30670819, NSFC-30772051, NSFC 30950010]
- Science and Technology Bureau of Sichuan Province [2009SZ0144]
- Doctoral Fund of Ministry of Education of China [20090181110026, 20090181120099]
Anti-TNF-alpha, therapies have been applied in RA treatment, but the regulatory effect of the drug on immune system is not clear. In this study, we included 33 active RA patients and divided them into two groups. One group received anti-TNF-alpha mAb + methotrexate for 24 weeks, the other group got placebo + methotrexate for the first 12 weeks and anti-TNF-alpha mAb + methotrexate for another 12 weeks. Circulatory regulatory T cell (Treg) and effector T cell (Teff) frequency was analyzed pre-therapy and week 12 and week 24 for both group patients by flowcytometry. Our results indicated significantly elevated Treg and decreased Teff at week 24 compared with pre-therapy and week 12 for both group patients, and a little higher Treg and lower Teff frequency in anti-TNF-alpha therapy group than in placebo therapy patients. Our results demonstrated anti-TNF-alpha therapy has regulatory effect on immune system of RA patients by promoting Treg proportion increase and suppressing Teff. (c) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据